Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14).
作者信息
Touzeau Cyrille, Le Gouill Steven, Mahé Béatrice, Boudreault Jean Samuel, Gastinne Thomas, Blin Nicolas, Caillon Hélène, Dousset Christelle, Amiot Martine, Moreau Philippe
机构信息
Department of Hematology, University Hospital, Nantes, France.
CRCNA, INSERM, CNRS, University of Nantes, Nantes, France.
出版信息
Haematologica. 2017 Mar;102(3):e112-e114. doi: 10.3324/haematol.2016.160408. Epub 2017 Jan 5.
Abstract
摘要
相似文献
1
Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14).在一名患有非常晚期难治性骨髓瘤且伴有t(11;14)易位的患者中，维奈克拉治疗后出现深度且持续的缓解。
Haematologica. 2017 Mar;102(3):e112-e114. doi: 10.3324/haematol.2016.160408. Epub 2017 Jan 5.
2
Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials.尽管有负面试验，但 Venetoclax 在 t(11;14)多发性骨髓瘤中的持续成功。
Oncology (Williston Park). 2024 Jun 10;38(6):239-241. doi: 10.46883/2024.25921023.
3
Natural history of multiple myeloma patients refractory to venetoclax: A single center experience.维奈托克难治性多发性骨髓瘤患者的自然病史：单中心经验。
Am J Hematol. 2021 Mar 1;96(3):E68-E71. doi: 10.1002/ajh.26064. Epub 2020 Dec 28.
4
Secondary plasma cell leukaemia treated with single agent venetoclax.采用单药维奈克拉治疗继发性浆细胞白血病。
Br J Haematol. 2020 Aug;190(4):e242-e245. doi: 10.1111/bjh.16858. Epub 2020 Jun 11.
5
Use of venetoclax in t(11;14) positive relapsed/refractory multiple myeloma: A systematic review.维奈托克在t(11;14)阳性复发/难治性多发性骨髓瘤中的应用：一项系统评价。
J Oncol Pharm Pract. 2024 Apr;30(3):552-561. doi: 10.1177/10781552231218999. Epub 2023 Dec 19.
6
Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14). Venetoclax 联合达雷妥尤单抗和地塞米松，加或不加硼替佐米，治疗伴有和不伴有 t(11;14)的复发/难治性多发性骨髓瘤的 I 期研究。
J Clin Oncol. 2021 Nov 10;39(32):3602-3612. doi: 10.1200/JCO.21.00443. Epub 2021 Aug 13.
7
Biologic Implications of t(11;14) in Multiple Myeloma Explained With a Case of Refractory Disease Sensitive to Venetoclax.用一例对维奈托克敏感的难治性疾病解释多发性骨髓瘤中t(11;14)的生物学意义
Clin Lymphoma Myeloma Leuk. 2020 Sep;20(9):e556-e559. doi: 10.1016/j.clml.2020.05.028. Epub 2020 Jun 14.
8
Impact of t(11;14) as a sole and concomitant abnormality on outcomes in multiple myeloma.t(11;14)作为唯一及伴随异常对多发性骨髓瘤预后的影响
Br J Haematol. 2021 Oct;195(1):e113-e116. doi: 10.1111/bjh.17627. Epub 2021 Jun 24.
9
Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence.伴有 t(11;14)相关性幼稚表型的多发性骨髓瘤 CD38 表达较低，BCL2 依赖性较高。
Cancer Sci. 2021 Sep;112(9):3645-3654. doi: 10.1111/cas.15073. Epub 2021 Jul 29.
10
Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma.维奈托克、硼替佐米和S63845（一种MCL1抑制剂）用于治疗多发性骨髓瘤。
J Pharm Pharmacol. 2020 May;72(5):728-737. doi: 10.1111/jphp.13240. Epub 2020 Feb 17.
引用本文的文献
1
Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14).伴有 t(6;14)易位的复发/难治性多发性骨髓瘤患者中有效的维奈托克治疗。
Pathol Oncol Res. 2023 Nov 10;29:1611375. doi: 10.3389/pore.2023.1611375. eCollection 2023.
2
Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency.t(11;14)多发性骨髓瘤的整合表观遗传和转录单细胞分析及其 BCL2 依赖性。
Blood. 2024 Jan 4;143(1):42-56. doi: 10.1182/blood.2023020276.
3
Efficacy and safety of venetoclax-based regimens for the treatment of relapsed/refractory multiple myeloma: a systemic review and meta-analysis.基于维奈托克的方案治疗复发/难治性多发性骨髓瘤的疗效和安全性：一项系统评价和荟萃分析。
Ther Adv Hematol. 2023 Mar 6;14:20406207231155028. doi: 10.1177/20406207231155028. eCollection 2023.
4
AL amyloidosis clonal plasma cells are regulated by microRNAs and dependent on anti-apoptotic BCL2 family members.AL 淀粉样变性克隆浆细胞受 microRNAs 调控，并依赖于抗凋亡 BCL2 家族成员。
Cancer Med. 2023 Apr;12(7):8199-8210. doi: 10.1002/cam4.5621. Epub 2023 Jan 24.
5
Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics.利用 BH3 模拟物在免疫球蛋白轻链淀粉样变性中内源性和治疗诱导的凋亡脆弱性。
Nat Commun. 2022 Oct 2;13(1):5789. doi: 10.1038/s41467-022-33461-z.
6
[Efficacy and safety analysis of BCL-2 inhibitor in relapsed/refractory multiple myeloma with t (11;14) in a single center].单中心中BCL-2抑制剂治疗伴t(11;14)复发/难治性多发性骨髓瘤的疗效与安全性分析
Zhonghua Xue Ye Xue Za Zhi. 2022 Feb 14;43(2):146-149. doi: 10.3760/cma.j.issn.0253-2727.2022.02.010.
7
Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor.多发性骨髓瘤治疗中免疫治疗之外的新型方法：美法仑氟芬、维奈克拉和塞利尼索的案例
Front Oncol. 2021 Sep 30;11:716751. doi: 10.3389/fonc.2021.716751. eCollection 2021.
8
Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications.免疫球蛋白轻链淀粉样变性的遗传发病机制：基本特征及临床应用
Exp Hematol Oncol. 2021 Jul 20;10(1):43. doi: 10.1186/s40164-021-00236-z.
9
Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies.克服血液系统恶性肿瘤对BCL2抑制剂维奈托克耐药的联合策略。
Cancer Cell Int. 2020 Oct 29;20(1):524. doi: 10.1186/s12935-020-01614-z.
10
Overview of Current Targeted Anti-Cancer Drugs for Therapy in Onco-Hematology.血液肿瘤治疗中当前靶向抗癌药物概述
Medicina (Kaunas). 2019 Jul 28;55(8):414. doi: 10.3390/medicina55080414.
本文引用的文献
1
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.国际骨髓瘤工作组多发性骨髓瘤反应和微小残留病评估的共识标准。
Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.
2
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.达雷妥尤单抗单药治疗治疗难治性多发性骨髓瘤患者（SIRIUS）：一项开放标签、随机、2 期试验。
Lancet. 2016 Apr 9;387(10027):1551-1560. doi: 10.1016/S0140-6736(15)01120-4. Epub 2016 Jan 7.
3
Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax.地塞米松治疗可促进多发性骨髓瘤对Bcl-2的依赖性，从而导致对维奈托克敏感。
Leukemia. 2016 May;30(5):1086-93. doi: 10.1038/leu.2015.350. Epub 2015 Dec 28.
4
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.卡非佐米和地塞米松与硼替佐米和地塞米松治疗复发或难治性多发性骨髓瘤患者的比较（ENDEAVOR）：一项随机、3 期、开放标签、多中心研究。
Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5.
5
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.在复发的慢性淋巴细胞白血病中使用维奈托克靶向BCL2
N Engl J Med. 2016 Jan 28;374(4):311-22. doi: 10.1056/NEJMoa1513257. Epub 2015 Dec 6.
6
BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics.BH3谱分析确定了多发性骨髓瘤中对Bcl-2家族成员的异质性依赖性，并预测了对BH3模拟物的敏感性。
Leukemia. 2016 Mar;30(3):761-4. doi: 10.1038/leu.2015.184. Epub 2015 Jul 15.
7
Multiple myeloma: from front-line to relapsed therapies.多发性骨髓瘤：从一线治疗到复发治疗
Am Soc Clin Oncol Educ Book. 2015:e504-11. doi: 10.14694/EdBook_AM.2015.35.e504.
8
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.国际骨髓瘤工作组更新了多发性骨髓瘤的诊断标准。
Lancet Oncol. 2014 Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26.
9
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.泊马度胺联合低剂量地塞米松与高剂量地塞米松单独用于治疗复发和难治性多发性骨髓瘤（MM-003）患者：一项随机、开放标签、3 期试验。
Lancet Oncol. 2013 Oct;14(11):1055-1066. doi: 10.1016/S1470-2045(13)70380-2. Epub 2013 Sep 3.
10
The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma.Bcl-2特异性BH3模拟物ABT-199：一种有前景的t(11;14)多发性骨髓瘤靶向治疗药物。
Leukemia. 2014 Jan;28(1):210-2. doi: 10.1038/leu.2013.216. Epub 2013 Jul 17.
Zotero 插件